PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 25, 2026MedicinaOpen Access

Comparison of the Efficacy of Pirfenidone and Nintedanib in the Treatment of Patients with Idiopathic Pulmonary Fibrosis—A Single-Center Experience

View Full Paper
Ask AI
Bookmark
Share

Authors

NTNikola TrboljevacSDSanja Dimic-JanjicMKMilica Kontic

Discussion

Loading...

Member takes

Overview

This retrospective cohort study compares treatment efficacy in IPF, showing no significant differences in outcomes between therapies.

Key Points

  • The study aims to compare the efficacy of pirfenidone and nintedanib in treating idiopathic pulmonary fibrosis (IPF).
  • Retrospective, single-center cohort study design
  • Included 76 IPF patients treated from February 2019 to February 2025
  • Analyzed patient demographics, lung function measurements including FVC and DLCO, HRCT patterns, and survival outcomes
  • Defined disease progression as ≥10% decline in FVC and/or DLCO after 12 months
  • No significant difference in mean annual decline in FVC between pirfenidone (-1.74%) and nintedanib (-2.38%)
  • DLCO declined similarly in both groups, with pirfenidone at -4.25% and nintedanib at -6.29%
  • Progression noted in 35 patients; no significant difference between therapies (p = 0.81)
  • Overall survival was 4.18 years on average, with no significant differences in survival between treatments (p = 0.159)

Cite This Study

Trboljevac et al. (2026) studied this question.

synapsesocial.com/papers/6975b20efeba4585c2d6d8d6https://doi.org/10.3390/medicina62010229
View Full Paper
Ask AI
Bookmark
Share